FMS

Business Context and Reporting Period

Company: Fresenius Medical Care AG & Co. KGaA
Filing Type: Form 6-K (Interim Report)
Reporting Period: Three and six months ended June 30, 2022
Business Overview: The world's leading provider of products and services for individuals with renal diseases, operating a vertically integrated business model comprising health care services (dialysis clinics) and health care products (machines, disposables, pharmaceuticals). Operations are segmented into North America, EMEA, Asia-Pacific, and Latin America.

Key Financial Metrics (Six Months Ended June 30, 2022)

Note: Revenue growth was primarily driven by foreign currency translation (+7%). At constant currency, revenue grew only 2%, while operating income declined 29%.

Material Changes vs. Prior Period

• Profitability Decline: Operating income decreased significantly due to higher personnel expenses, inflationary cost increases (energy, raw materials), and the impact of the Humacyte investment remeasurement. Gross profit margin contracted from 29.2% to 28.0%.
• Volume Trends: Total dialysis treatments decreased by 1% (Same Market Treatment Growth of -1.5%), driven by excess patient mortality rates due to COVID-19, particularly in North America and Latin America.
• Segment Performance:
  • North America: Revenue up 10% (as reported), but operating income down 19% due to higher implicit price concessions and personnel costs.
  • EMEA: Operating income down 21% due to the war in Ukraine, hyperinflation in Turkey, and inflationary pressures.
  • Latin America: Operating income down 46% (to €5M) driven by inflation and currency effects.
  • Asia-Pacific: Operating income remained flat (€170M) despite revenue growth, offset by inflation and lower margin business growth.
• Cash Flow: Net cash from operating activities decreased to €910M (from €1,129M), largely due to the recoupment of advanced Medicare payments received in 2020.

Guidance, Outlook, and Risks

• Leadership Transition: CEO Rice Powell is stepping down on September 30, 2022, succeeded by Dr. Carla Kriwet on October 1, 2022.
• Strategic Initiatives: The company is executing the "FME25 Program" to transform its operating model into two global segments (Health Care Services and Health Care Products) by 2023. A new value-based care entity combining Fresenius Health Partners, InterWell Health, and Cricket Health is pending regulatory approval.
• Reimbursement Environment: U.S. Medicare sequestration (spending cuts) resumed at 1% for Q2 2022 and will return to 2% in July 2022. CMS proposed a 2.4% rate increase for CY 2023.
• Key Risks:
  • Geopolitical: The war in Ukraine has increased energy costs, supply chain disruptions, and cyber security risks. Assets in Russia/Ukraine represent <1.5% of total assets.
  • Regulatory: Ongoing investigations and litigation regarding the Foreign Corrupt Practices Act (FCPA) and False Claims Act. A non-prosecution agreement with the DOJ/SEC is scheduled to terminate in December 2022.
  • Operational: Labor shortages and inflationary pressures on wages and supplies.

Investor Verification Checklist

• Constant Currency Performance: Verify organic growth rates by stripping out the ~7% positive currency translation impact on revenue.
• U.S. Reimbursement Impact: Monitor the effect of the full 2% Medicare sequestration resuming in July 2022 and the finalization of the CY 2023 ESRD PPS rule.
• War in Ukraine Exposure: Assess the long-term impact of energy price volatility and supply chain disruptions on EMEA margins, beyond the immediate €23M special item charge.
• Humacyte Investment: Review the volatility of the Humacyte investment remeasurement (€78M charge in H1 2022) and its impact on future earnings.
• Liquidity Position: Confirm the company's ability to return to its 3.0x-3.5x net leverage target by year-end 2022 given the current 3.6x ratio.